Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vicarious Surgical ( (RBOT) ) has provided an update.
On July 30, 2025, Vicarious Surgical‘s Board of Directors appointed Stephen From as the new Chief Executive Officer, effective August 7, 2025, while Adam Sachs, the current CEO and co-founder, will transition to the role of President. This leadership change is seen as a strategic move to leverage Mr. From’s extensive experience in the healthcare and financial sectors to advance the company’s mission of transforming surgical care through innovative robotics. The appointment also includes a stock option grant to Mr. From as an inducement to join the company, reflecting a significant step in Vicarious Surgical’s growth and industry positioning.
The most recent analyst rating on (RBOT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Vicarious Surgical stock, see the RBOT Stock Forecast page.
Spark’s Take on RBOT Stock
According to Spark, TipRanks’ AI Analyst, RBOT is a Underperform.
Vicarious Surgical’s stock score reflects significant financial challenges as a pre-revenue company with high cash burn, offset by a moderately stable balance sheet. Technical analysis indicates bearish sentiment, compounded by valuation challenges due to negative earnings. While the earnings call showed strategic advancements, supply chain delays and NYSE compliance issues pose risks. Successful clinical trials and improved cash management will be critical for future performance.
To see Spark’s full report on RBOT stock, click here.
More about Vicarious Surgical
Vicarious Surgical, founded in 2014 and based in Waltham, Massachusetts, is a next-generation surgical robotics company. It focuses on developing innovative technology aimed at enhancing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The company utilizes proprietary human-like surgical robots to enable minimally invasive surgeries and is supported by notable investors including Bill Gates and Khosla Ventures.
Average Trading Volume: 19,110
Technical Sentiment Signal: Sell
Current Market Cap: $54.1M
Find detailed analytics on RBOT stock on TipRanks’ Stock Analysis page.